Cargando…
Mycobacterium tuberculosis Sub-Lineage 4.2.2/SIT149 as Dominant Drug-Resistant Clade in Northwest Ethiopia 2020–2022: In-silico Whole-Genome Sequence Analysis
INTRODUCTION: Drug resistance (DR) in Mycobacterium tuberculosis complex (MTBC) is mainly associated with certain lineages and varies across regions and countries. The Beijing genotype is the leading resistant lineage in Asia and western countries. M. tuberculosis (Mtb) (sub) lineages responsible fo...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614653/ https://www.ncbi.nlm.nih.gov/pubmed/37908783 http://dx.doi.org/10.2147/IDR.S429001 |
_version_ | 1785129066568876032 |
---|---|
author | Mekonnen, Daniel Munshea, Abaineh Nibret, Endalkachew Adnew, Bethlehem Getachew, Hailu Kebede, Amiro Gebrewahid, Ananya Herrera-Leon, Silvia Aramendia, Aranzazu Amor Benito, Agustín Abascal, Estefanía Jacqueline, Camille Aseffa, Abraham Herrera-Leon, Laura |
author_facet | Mekonnen, Daniel Munshea, Abaineh Nibret, Endalkachew Adnew, Bethlehem Getachew, Hailu Kebede, Amiro Gebrewahid, Ananya Herrera-Leon, Silvia Aramendia, Aranzazu Amor Benito, Agustín Abascal, Estefanía Jacqueline, Camille Aseffa, Abraham Herrera-Leon, Laura |
author_sort | Mekonnen, Daniel |
collection | PubMed |
description | INTRODUCTION: Drug resistance (DR) in Mycobacterium tuberculosis complex (MTBC) is mainly associated with certain lineages and varies across regions and countries. The Beijing genotype is the leading resistant lineage in Asia and western countries. M. tuberculosis (Mtb) (sub) lineages responsible for most drug resistance in Ethiopia are not well described. Hence, this study aimed to identify the leading drug resistance sub-lineages and characterize first-line anti-tuberculosis drug resistance-associated single nucleotide polymorphisms (SNPs). METHODS: A facility-based cross-sectional study was conducted in 2020–2022 among new and presumptive multidrug resistant-TB (MDR-TB) cases in Northwest Ethiopia. Whole-genome sequencing (WGS) was performed on 161 isolates using Illumina NovaSeq 6000 technology. The SNP mutations associated with drug resistance were identified using MtbSeq and TB profiler Bioinformatics softwares. RESULTS: Of the 146 Mtb isolates that were successfully genotyped, 20 (13.7%) harbored one or more resistance-associated SNPs. L4.2.2.ETH was the leading drug-resistant sub-lineage, accounting for 10/20 (50%) of the resistant Mtb. MDR-TB isolates showed extensive mutations against first-line anti-TB drugs. Ser450Leu/(tcg/tTg) for Rifampicin (RIF), Ser315Thr/(agc/aCc) for Isoniazid (INH), Met306Ile/(atg/atA(C)) for Ethambutol (EMB), and Gly69Asp for Streptomycin (STR) were the leading resistance associated mutations which accounted for 56.5%, 89.5%, 47%, and 29.4%, respectively. The presence of both clustered and non-clustered drug resistance (DR) isolates indicated that the epidemics is driven by both new DR development and acquired resistance. CONCLUSION: The high prevalence of drug-resistant TB due to geographically restricted sub-lineages (L4.2.2.ETH) indicates the ongoing local micro epidemics. The Mtb drug resistance surveillance system must be improved. Further evolutionary analysis of L4.2.2.ETH strain is highly desirable to understand evolutionary forces that leads L4.2.2.ETH in to high level DR and transmissible sub-lineage. |
format | Online Article Text |
id | pubmed-10614653 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-106146532023-10-31 Mycobacterium tuberculosis Sub-Lineage 4.2.2/SIT149 as Dominant Drug-Resistant Clade in Northwest Ethiopia 2020–2022: In-silico Whole-Genome Sequence Analysis Mekonnen, Daniel Munshea, Abaineh Nibret, Endalkachew Adnew, Bethlehem Getachew, Hailu Kebede, Amiro Gebrewahid, Ananya Herrera-Leon, Silvia Aramendia, Aranzazu Amor Benito, Agustín Abascal, Estefanía Jacqueline, Camille Aseffa, Abraham Herrera-Leon, Laura Infect Drug Resist Original Research INTRODUCTION: Drug resistance (DR) in Mycobacterium tuberculosis complex (MTBC) is mainly associated with certain lineages and varies across regions and countries. The Beijing genotype is the leading resistant lineage in Asia and western countries. M. tuberculosis (Mtb) (sub) lineages responsible for most drug resistance in Ethiopia are not well described. Hence, this study aimed to identify the leading drug resistance sub-lineages and characterize first-line anti-tuberculosis drug resistance-associated single nucleotide polymorphisms (SNPs). METHODS: A facility-based cross-sectional study was conducted in 2020–2022 among new and presumptive multidrug resistant-TB (MDR-TB) cases in Northwest Ethiopia. Whole-genome sequencing (WGS) was performed on 161 isolates using Illumina NovaSeq 6000 technology. The SNP mutations associated with drug resistance were identified using MtbSeq and TB profiler Bioinformatics softwares. RESULTS: Of the 146 Mtb isolates that were successfully genotyped, 20 (13.7%) harbored one or more resistance-associated SNPs. L4.2.2.ETH was the leading drug-resistant sub-lineage, accounting for 10/20 (50%) of the resistant Mtb. MDR-TB isolates showed extensive mutations against first-line anti-TB drugs. Ser450Leu/(tcg/tTg) for Rifampicin (RIF), Ser315Thr/(agc/aCc) for Isoniazid (INH), Met306Ile/(atg/atA(C)) for Ethambutol (EMB), and Gly69Asp for Streptomycin (STR) were the leading resistance associated mutations which accounted for 56.5%, 89.5%, 47%, and 29.4%, respectively. The presence of both clustered and non-clustered drug resistance (DR) isolates indicated that the epidemics is driven by both new DR development and acquired resistance. CONCLUSION: The high prevalence of drug-resistant TB due to geographically restricted sub-lineages (L4.2.2.ETH) indicates the ongoing local micro epidemics. The Mtb drug resistance surveillance system must be improved. Further evolutionary analysis of L4.2.2.ETH strain is highly desirable to understand evolutionary forces that leads L4.2.2.ETH in to high level DR and transmissible sub-lineage. Dove 2023-10-26 /pmc/articles/PMC10614653/ /pubmed/37908783 http://dx.doi.org/10.2147/IDR.S429001 Text en © 2023 Mekonnen et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Mekonnen, Daniel Munshea, Abaineh Nibret, Endalkachew Adnew, Bethlehem Getachew, Hailu Kebede, Amiro Gebrewahid, Ananya Herrera-Leon, Silvia Aramendia, Aranzazu Amor Benito, Agustín Abascal, Estefanía Jacqueline, Camille Aseffa, Abraham Herrera-Leon, Laura Mycobacterium tuberculosis Sub-Lineage 4.2.2/SIT149 as Dominant Drug-Resistant Clade in Northwest Ethiopia 2020–2022: In-silico Whole-Genome Sequence Analysis |
title | Mycobacterium tuberculosis Sub-Lineage 4.2.2/SIT149 as Dominant Drug-Resistant Clade in Northwest Ethiopia 2020–2022: In-silico Whole-Genome Sequence Analysis |
title_full | Mycobacterium tuberculosis Sub-Lineage 4.2.2/SIT149 as Dominant Drug-Resistant Clade in Northwest Ethiopia 2020–2022: In-silico Whole-Genome Sequence Analysis |
title_fullStr | Mycobacterium tuberculosis Sub-Lineage 4.2.2/SIT149 as Dominant Drug-Resistant Clade in Northwest Ethiopia 2020–2022: In-silico Whole-Genome Sequence Analysis |
title_full_unstemmed | Mycobacterium tuberculosis Sub-Lineage 4.2.2/SIT149 as Dominant Drug-Resistant Clade in Northwest Ethiopia 2020–2022: In-silico Whole-Genome Sequence Analysis |
title_short | Mycobacterium tuberculosis Sub-Lineage 4.2.2/SIT149 as Dominant Drug-Resistant Clade in Northwest Ethiopia 2020–2022: In-silico Whole-Genome Sequence Analysis |
title_sort | mycobacterium tuberculosis sub-lineage 4.2.2/sit149 as dominant drug-resistant clade in northwest ethiopia 2020–2022: in-silico whole-genome sequence analysis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614653/ https://www.ncbi.nlm.nih.gov/pubmed/37908783 http://dx.doi.org/10.2147/IDR.S429001 |
work_keys_str_mv | AT mekonnendaniel mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis AT munsheaabaineh mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis AT nibretendalkachew mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis AT adnewbethlehem mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis AT getachewhailu mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis AT kebedeamiro mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis AT gebrewahidananya mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis AT herreraleonsilvia mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis AT aramendiaaranzazuamor mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis AT benitoagustin mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis AT abascalestefania mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis AT jacquelinecamille mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis AT aseffaabraham mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis AT herreraleonlaura mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis |